Pituitary and Hypothalamic Hormones and Analogues

DrugDrug NameDrug Indication
DB00010SermorelinFor the treatment of dwarfism, prevention of HIV-induced weight loss
DB00035Desmopressin- Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal). - Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral). - Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).
DB00050CetrorelixFor the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
DB00052SomatotropinFor treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
DB00082PegvisomantPegvisomant is a growth hormone receptor antagonist used for the treatment of acromegaly.
DB00104OctreotideFor treatment of acromegaly and reduction of side effects from cancer chemotherapy
DB00644GonadorelinFor evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
DB00666NafarelinFor treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
DB01277MecaserminFor the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH [A2322]. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
DB01282CarbetocinUsed to control postpartum hemorrhage and bleeding after giving birth.
DB01284TetracosactideFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB01285CorticotropinFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB02638TerlipressinCommonly used to stop bleeding of varices in the food pipe (oesophagus).
DB04894VapreotideFor the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
DB06663PasireotideFor the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
DB06785GanirelixFor the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
DB06791LanreotideLanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2)
DB08869TesamorelinTesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
DB09098SomatremSomatrem is a recombinant human growth hormone indicated for: (a) treatment of paediatric patients with growth failure due to growth hormone deficiency (GHD), (b) treatment of paediatric patients with growth failure due to idiopathic short stature (ISS), (c) treatment of paediatric patients with growth failure due to Turner syndrome (TS), (d) treatment of paediatric patients with growth failure due to chronic kidney disease (CKD) up to the time of renal transplantation, (e) treatment of adults with childhood-onset GHD, or (f) treatment of adults with adult-onset GHD [FDA Label].
DB09099SomatostatinFor the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established.
DB13464OrnipressinNot Available
DB13798DemoxytocinNot Available
DB00024Thyrotropin alfaFor detection of residueal or recurrent thyroid cancer
DB00107OxytocinUsed for labor induction, augmentation of labor, postpartum abbreviation of third stage of labor, postpartum control of uterine bleeding, termination of pregnancy and for the evaluation of fetal respiratory capability. Oxytocin cannot be used for elective induction of labor, there must be a clear medical requirement.
DB14642LypressinNot Available
DB14751Mecasermin rinfabateMecasermin rinfabate was approved for treatment of severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH)[A176020]. Severe primary IGF-1 deficiency is defined by:[FDA Label] A) height standard deviation (SD) score less than or equal to 3 SD below normal B) basal IGF-1 SD score less than or equal to 3 SD below normal C) normal or above normal levels of growth hormone In 2007, Insmed (Mecasermin rinfabate's manufacturer) made an agreement with Tercica (Mecasermin's manufacturer) that Mecasermin would no longer be available for this indication but could be developed for non short stature conditions such as severe insulin resistance, myotonic muscular dystrophy, and HIV associated adipose redistribution syndrome[A176125].
DrugDrug NameTargetType
DB00010SermorelinGrowth hormone-releasing hormone receptortarget
DB00035DesmopressinVasopressin V1a receptortarget
DB00035DesmopressinVasopressin V1b receptortarget
DB00035DesmopressinVasopressin V2 receptortarget
DB00035DesmopressinProstaglandin G/H synthase 1enzyme
DB00035DesmopressinProstaglandin G/H synthase 2enzyme
DB00050CetrorelixLutropin-choriogonadotropic hormone receptortarget
DB00050CetrorelixGonadotropin-releasing hormone receptortarget
DB00052SomatotropinGrowth hormone receptortarget
DB00052SomatotropinProlactin receptortarget
DB00082PegvisomantGrowth hormone receptortarget
DB00082PegvisomantSterol 26-hydroxylase, mitochondrialenzyme
DB00082PegvisomantGlutamine synthetaseenzyme
DB00082PegvisomantCytochrome P450 2C18enzyme
DB00082PegvisomantCytochrome P450 3A4enzyme
DB00082PegvisomantCholinesteraseenzyme
DB00082PegvisomantCytochrome P450 2C19enzyme
DB00082PegvisomantCytochrome P450 4A11enzyme
DB00104OctreotideSomatostatin receptor type 1target
DB00104OctreotideSomatostatin receptor type 5target
DB00104OctreotideSomatostatin receptor type 2target
DB00104OctreotideMyeloperoxidaseenzyme
DB00104OctreotideCytochrome P450 3A4enzyme
DB00644GonadorelinGonadotropin-releasing hormone receptortarget
DB00644GonadorelinPutative gonadotropin-releasing hormone II receptortarget
DB00666NafarelinGonadotropin-releasing hormone receptortarget
DB00666NafarelinPutative gonadotropin-releasing hormone II receptortarget
DB01277MecaserminInsulin-like growth factor 1 receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3target
DB01277MecaserminInsulin receptortarget
DB01277MecaserminCation-independent mannose-6-phosphate receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3carrier
DB01277MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
DB01277MecaserminInsulin-like growth factor-binding protein 1carrier
DB01277MecaserminInsulin-like growth factor-binding protein 2carrier
DB01277MecaserminInsulin-like growth factor-binding protein 4carrier
DB01277MecaserminInsulin-like growth factor-binding protein 5carrier
DB01277MecaserminInsulin-like growth factor-binding protein 6carrier
DB01282CarbetocinOxytocin receptortarget
DB01284TetracosactideAdrenocorticotropic hormone receptortarget
DB01285CorticotropinAdrenocorticotropic hormone receptortarget
DB01285CorticotropinCorticoliberintarget
DB01285Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB01285Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB01285Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB01285CorticotropinCytochrome P450 3A4enzyme
DB02638TerlipressinVasopressin V1a receptortarget
DB02638TerlipressinVasopressin V2 receptortarget
DB02638TerlipressinVasopressin V1b receptortarget
DB04894VapreotideSubstance-P receptortarget
DB04894VapreotideSomatostatin receptor type 2target
DB04894VapreotideSomatostatin receptor type 5target
DB04894VapreotideCytochrome P450 3A4enzyme
DB06663PasireotideSomatostatin receptor type 1target
DB06663PasireotideSomatostatin receptor type 2target
DB06663PasireotideSomatostatin receptor type 3target
DB06663PasireotideSomatostatin receptor type 5target
DB06663PasireotideCytochrome P450 3A4enzyme
DB06785GanirelixGonadotropin-releasing hormone receptortarget
DB06791LanreotideSomatostatin receptor type 2target
DB06791LanreotideSomatostatin receptor type 5target
DB06791LanreotideCytochrome P450 3A4enzyme
DB08869TesamorelinGrowth hormone-releasing hormone receptortarget
DB09098SomatremGrowth hormone receptortarget
DB09098SomatremInsulin-like growth factor 1 receptortarget
DB09099SomatostatinSomatostatin receptor type 1target
DB09099SomatostatinSomatostatin receptor type 2target
DB09099SomatostatinSomatostatin receptor type 3target
DB09099SomatostatinSomatostatin receptor type 4target
DB09099SomatostatinSomatostatin receptor type 5target
DB09099SomatostatinMultidrug resistance protein 1transporter
DB09099SomatostatinCytochrome P450 3A4enzyme
DB00024Thyrotropin alfaThyrotropin receptortarget
DB00107OxytocinOxytocin-neurophysin 1target
DB00107OxytocinOxytocin receptortarget
DB00107OxytocinProlyl endopeptidaseenzyme
DB14642LypressinVasopressin V1a receptortarget
DB14642LypressinVasopressin V2 receptortarget
DB14642LypressinVasopressin V1b receptortarget
DB14642LypressinCanalicular multispecific organic anion transporter 1transporter
DB14751Mecasermin rinfabateInsulin-like growth factor 1 receptortarget
DB14751Mecasermin rinfabateInsulin receptortarget
DB14751Mecasermin rinfabateCation-independent mannose-6-phosphate receptortarget